Pyxis Oncology Inc
NASDAQ:PYXS

Watchlist Manager
Pyxis Oncology Inc Logo
Pyxis Oncology Inc
NASDAQ:PYXS
Watchlist
Price: 1.32 USD 1.54% Market Closed
Market Cap: 78.5m USD
Have any thoughts about
Pyxis Oncology Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one PYXS stock under the Base Case scenario is 1.97 USD. Compared to the current market price of 1.32 USD, Pyxis Oncology Inc is Undervalued by 33%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PYXS Relative Value
Base Case
1.97 USD
Undervaluation 33%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.9
P/S
P/S
Price to Sales
4.9
vs History
5
vs Industry
44
Median 3Y
0
Median 5Y
0
Industry
7.7
Forward
5.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-1.1
Median 5Y
-1.2
Industry
22.3
Forward
-1.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-1.7
Median 5Y
-1.7
Industry
21.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-1.6
Industry
24.2
More Details
0.5
P/B
P/B
Price to Book Value
0.5
vs History
7
vs Industry
61
Median 3Y
0.6
Median 5Y
0.6
Industry
2.5
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
2
vs Industry
75
Median 3Y
0
Median 5Y
0
Industry
7.7
Forward
-4.7
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
2
vs Industry
74
Median 3Y
0
Median 5Y
0
Industry
9.4
More Details
1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
1
vs History
vs Industry
27
Median 3Y
0.5
Median 5Y
0.4
Industry
4.3
Forward
0.5
More Details
1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
1
vs History
vs Industry
26
Median 3Y
0.5
Median 5Y
0.4
Industry
4
Forward
0.9
More Details
1.2
EV/OCF
EV/OCF
Enterprise Value to OCF
1.2
vs History
vs Industry
27
Median 3Y
0.6
Median 5Y
0.6
Industry
5.8
More Details
1.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
1.2
vs History
vs Industry
24
Median 3Y
0.6
Median 5Y
0.5
Industry
3.8
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
10
vs Industry
67
Median 3Y
-1.2
Median 5Y
-1.1
Industry
4.6
More Details

Multiples Across Competitors

PYXS Competitors Multiples
Pyxis Oncology Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Pyxis Oncology Inc
NASDAQ:PYXS
78.5m USD 4.9 -1.4 1 1
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 813 451.7 -179 721.7 -218 239.4 -215 749
US
Abbvie Inc
NYSE:ABBV
340.8B USD 6.1 67.1 16.5 25.4
US
Amgen Inc
NASDAQ:AMGN
156.4B USD 4.7 38.2 14.9 25.4
US
Gilead Sciences Inc
NASDAQ:GILD
129.7B USD 4.6 1 029.2 11.5 11.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.9B USD 10.7 -220.2 24.2 25.5
US
Epizyme Inc
F:EPE
94.1B EUR 1 863.1 -475.4 -517.7 -503.9
AU
CSL Ltd
ASX:CSL
124.1B AUD 5.3 29.9 18.6 23.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.8B USD 5.2 16.7 11.1 12.4
US
Seagen Inc
F:SGT
39.3B EUR 17.9 -55 -59.1 -53.4
NL
argenx SE
XBRU:ARGX
36.3B EUR 17.4 -337.7 -160.2 -104.3
P/S Multiple
Revenue Growth P/S to Growth
US
Pyxis Oncology Inc
NASDAQ:PYXS
Average P/S: 3 437 762.9
4.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
37 813 451.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
6%
1
US
Amgen Inc
NASDAQ:AMGN
4.7
3%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
4.6
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.7
9%
1.2
US
E
Epizyme Inc
F:EPE
1 863.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.3
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.2
8%
0.6
US
S
Seagen Inc
F:SGT
17.9
30%
0.6
NL
argenx SE
XBRU:ARGX
17.4
55%
0.3
P/E Multiple
Earnings Growth PEG
US
Pyxis Oncology Inc
NASDAQ:PYXS
Average P/E: 236.2
Negative Multiple: -1.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -179 721.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
67.1
73%
0.9
US
Amgen Inc
NASDAQ:AMGN
38.2
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
1 029.2
22%
46.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -220.2 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -475.4 N/A N/A
AU
CSL Ltd
ASX:CSL
29.9
18%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -55 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -337.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Pyxis Oncology Inc
NASDAQ:PYXS
Average EV/EBITDA: 14
1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 239.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
9%
1.8
US
Amgen Inc
NASDAQ:AMGN
14.9
12%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.5
5%
2.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -517.7 N/A N/A
AU
CSL Ltd
ASX:CSL
18.6
12%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -160.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Pyxis Oncology Inc
NASDAQ:PYXS
Average EV/EBIT: 17.8
1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 749 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.4
25%
1
US
Amgen Inc
NASDAQ:AMGN
25.4
27%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
11.5
11%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
15%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -503.9 N/A N/A
AU
CSL Ltd
ASX:CSL
23.2
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.4
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.3 N/A N/A

See Also

Summary
PYXS intrinsic value, competitors valuation, and company profile.
DCF Valuation
PYXS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PYXS stock valuation using valuation multiples.
Wall Street Estimates
PYXS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PYXS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 228,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.